However, the study, carried out by a team of primarily U.K.-based academics, has found that Molnupiravir might not always succeed in eliminating the virus. Instead, it could inadvertently facilitate the spread of mutated versions of the virus.
Molnupiravir has been widely used in various countries as it has shown promising results in helping high-risk individuals avoid severe COVID symptoms. However, the researchers utilized a global database to track virus mutations and discovered distinct changes that deviated from the typical COVID mutations. These unique patterns were closely associated with patients who had received treatment with Molnupiravir. Furthermore, these atypical mutations were found to have increased in incidence during 2022, coinciding with the widespread adoption of Molnupiravir.
It is crucial to closely examine these findings to assess any potential risks associated with this antiviral drug. The study highlights a need for further research to understand the mechanisms by which Molnupiravir may contribute to the emergence and propagation of new variants of the virus.
Read now: WHO includes Merck’s antiviral in its treatment guidelines for patients with nonsevere disease.
Molnupiravir Creates Genetically Divergent Viruses with Unknown Consequences
A recent study conducted by researchers from various institutions including the University of Cape Town in South Africa has revealed concerning findings about the antiviral medication, molnupiravir. According to the study, molnupiravir has the ability to create genetically divergent viruses that not only replicate but also transmit among individuals. The implications of this discovery for global public health remain unknown.
It is worth noting that the mutations linked to molnupiravir were predominantly observed in older individuals who are more susceptible to severe forms of the virus. This correlation could be attributed to the higher usage of antiviral medications among this age group. Additionally, these mutations were more prevalent in samples obtained from countries where molnupiravir was widely prescribed, including the U.S., U.K., Australia, and Japan.
The sales of molnupiravir, marketed under the name Lagevrio, have experienced a substantial increase. In 2022, sales reached $5.7 billion compared to $952 million in 2021.
Merck, the pharmaceutical company behind molnupiravir, has yet to respond to inquiries regarding the study. Meanwhile, Merck’s stock has seen a slight decline of 0.7% on Monday and a 5% decrease year-to-date, whereas the S&P 500 has gained 13%.
- *Merck’s first-quarter earnings beat estimates, even as COVID-19 treatment sales plummet
- *Moderna, Merck combo cancer-vaccine treatment shows ‘significant’ promise
